Upcoming Dividend • May 05
Upcoming dividend of CN¥0.16 per share Eligible shareholders must have bought the stock before 12 May 2026. Payment date: 12 May 2026. Payout ratio is a comfortable 32% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Chinese dividend payers (1.9%). Lower than average of industry peers (1.2%). Reported Earnings • Apr 23
First quarter 2026 earnings released: EPS: CN¥0.17 (vs CN¥0.20 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.17 (down from CN¥0.20 in 1Q 2025). Revenue: CN¥771.3m (up 12% from 1Q 2025). Net income: CN¥42.1m (down 18% from 1Q 2025). Profit margin: 5.5% (down from 7.4% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings. Announcement • Mar 30
Anhui Huaheng Biotechnology Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026 Anhui Huaheng Biotechnology Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026 Major Estimate Revision • Mar 24
Consensus EPS estimates fall by 18%, revenue upgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from CN¥3.08b to CN¥3.16b. EPS estimate fell from CN¥1.42 to CN¥1.17 per share. Net income forecast to grow 121% next year vs 49% growth forecast for Chemicals industry in China. Consensus price target down from CN¥44.04 to CN¥42.54. Share price fell 14% to CN¥29.36 over the past week. Announcement • Mar 17
Anhui Huaheng Biotechnology Co., Ltd., Annual General Meeting, Apr 08, 2026 Anhui Huaheng Biotechnology Co., Ltd., Annual General Meeting, Apr 08, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui China Reported Earnings • Mar 05
Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2025 results: EPS: CN¥0.52 (down from CN¥0.82 in FY 2024). Revenue: CN¥2.89b (up 33% from FY 2024). Net income: CN¥130.8m (down 31% from FY 2024). Profit margin: 4.5% (down from 8.7% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 51%. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥41.34, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 27x in the Chemicals industry in China. Total loss to shareholders of 45% over the past three years. Announcement • Dec 26
Anhui Huaheng Biotechnology Co., Ltd. to Report Fiscal Year 2025 Results on Mar 25, 2026 Anhui Huaheng Biotechnology Co., Ltd. announced that they will report fiscal year 2025 results on Mar 25, 2026 Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥32.27, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 24x in the Chemicals industry in China. Total loss to shareholders of 56% over the past three years. Reported Earnings • Oct 28
Third quarter 2025 earnings released: EPS: CN¥0.21 (vs CN¥0.087 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.21 (up from CN¥0.087 in 3Q 2024). Revenue: CN¥704.4m (up 35% from 3Q 2024). Net income: CN¥52.7m (up 161% from 3Q 2024). Profit margin: 7.5% (up from 3.9% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 20% per year. Announcement • Sep 30
Anhui Huaheng Biotechnology Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025 Anhui Huaheng Biotechnology Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025 Major Estimate Revision • Sep 02
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥2.72b to CN¥2.48b. EPS estimate also fell from CN¥1.13 per share to CN¥1.01 per share. Net income forecast to grow 86% next year vs 49% growth forecast for Chemicals industry in China. Consensus price target up from CN¥36.90 to CN¥41.28. Share price rose 5.7% to CN¥38.69 over the past week. Declared Dividend • Jul 07
Dividend of CN¥0.25 announced Shareholders will receive a dividend of CN¥0.25. Ex-date: 10th July 2025 Payment date: 10th July 2025 Dividend yield will be 0.8%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (38% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 168% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Jun 30
Anhui Huaheng Biotechnology Co., Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Anhui Huaheng Biotechnology Co., Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 Major Estimate Revision • May 09
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥2.73b to CN¥2.67b. EPS estimate also fell from CN¥1.26 per share to CN¥1.12 per share. Net income forecast to grow 95% next year vs 42% growth forecast for Chemicals industry in China. Consensus price target down from CN¥38.65 to CN¥36.90. Share price rose 2.1% to CN¥28.43 over the past week. Major Estimate Revision • Apr 29
Consensus EPS estimates fall by 28% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥3.01b to CN¥2.82b. EPS estimate also fell from CN¥1.76 per share to CN¥1.26 per share. Net income forecast to grow 112% next year vs 51% growth forecast for Chemicals industry in China. Consensus price target down from CN¥44.03 to CN¥38.65. Share price was steady at CN¥27.64 over the past week. Reported Earnings • Apr 24
First quarter 2025 earnings released: EPS: CN¥0.20 (vs CN¥0.33 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.20 (down from CN¥0.33 in 1Q 2024). Revenue: CN¥687.1m (up 35% from 1Q 2024). Net income: CN¥51.1m (down 32% from 1Q 2024). Profit margin: 7.4% (down from 15% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Price Target Changed • Apr 23
Price target decreased by 8.9% to CN¥43.00 Down from CN¥47.20, the current price target is an average from 4 analysts. New target price is 53% above last closing price of CN¥28.09. Stock is down 62% over the past year. The company is forecast to post earnings per share of CN¥1.56 for next year compared to CN¥0.86 last year. Announcement • Apr 23
Anhui Huaheng Biotechnology Co., Ltd., Annual General Meeting, May 13, 2025 Anhui Huaheng Biotechnology Co., Ltd., Annual General Meeting, May 13, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui China Announcement • Mar 28
Anhui Huaheng Biotechnology Co., Ltd. to Report Q1, 2025 Results on Apr 23, 2025 Anhui Huaheng Biotechnology Co., Ltd. announced that they will report Q1, 2025 results on Apr 23, 2025 Reported Earnings • Feb 26
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2024 results: EPS: CN¥0.86 (down from CN¥1.96 in FY 2023). Revenue: CN¥2.18b (up 13% from FY 2023). Net income: CN¥199.8m (down 56% from FY 2023). Profit margin: 9.1% (down from 23% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) missed analyst estimates by 3.6%. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥33.76, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 20x in the Chemicals industry in China. Total loss to shareholders of 41% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥15.21 per share. Major Estimate Revision • Jan 22
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥2.18b to CN¥2.07b. EPS estimate also fell from CN¥1.01 per share to CN¥0.892 per share. Net income forecast to grow 39% next year vs 50% growth forecast for Chemicals industry in China. Consensus price target down from CN¥47.20 to CN¥45.37. Share price was steady at CN¥27.30 over the past week. Price Target Changed • Jan 21
Price target decreased by 8.0% to CN¥45.37 Down from CN¥49.29, the current price target is an average from 3 analysts. New target price is 65% above last closing price of CN¥27.42. Stock is down 63% over the past year. The company is forecast to post earnings per share of CN¥0.89 for next year compared to CN¥1.96 last year. Announcement • Dec 27
Anhui Huaheng Biotechnology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 23, 2025 Anhui Huaheng Biotechnology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 23, 2025 Price Target Changed • Dec 14
Price target decreased by 16% to CN¥60.31 Down from CN¥71.99, the current price target is an average from 3 analysts. New target price is 68% above last closing price of CN¥35.82. Stock is down 56% over the past year. The company is forecast to post earnings per share of CN¥1.53 for next year compared to CN¥1.96 last year. Major Estimate Revision • Nov 04
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥2.64b to CN¥2.34b. EPS estimate fell from CN¥1.80 to CN¥1.02 per share. Net income forecast to grow 90% next year vs 55% growth forecast for Chemicals industry in China. Consensus price target down from CN¥71.99 to CN¥69.07. Share price fell 12% to CN¥33.60 over the past week. Reported Earnings • Oct 29
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: CN¥0.087 (down from CN¥0.56 in 3Q 2023). Revenue: CN¥522.8m (up 1.7% from 3Q 2023). Net income: CN¥20.2m (down 84% from 3Q 2023). Profit margin: 3.9% (down from 25% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 44%. Earnings per share (EPS) also missed analyst estimates by 88%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 02
Investor sentiment improves as stock rises 39% After last week's 39% share price gain to CN¥39.70, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 46% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥73.83 per share. Announcement • Sep 30
Anhui Huaheng Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024 Anhui Huaheng Biotechnology Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 New Risk • Sep 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (7.4% operating cash flow to total debt). High level of non-cash earnings (64% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.9% average weekly change). Major Estimate Revision • Sep 03
Consensus revenue estimates fall by 17% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥3.17b to CN¥2.64b. EPS estimate fell from CN¥2.77 to CN¥1.91 per share. Net income forecast to grow 42% next year vs 46% growth forecast for Chemicals industry in China. Consensus price target down from CN¥93.60 to CN¥71.99. Share price fell 6.7% to CN¥29.93 over the past week. Price Target Changed • Aug 28
Price target decreased by 23% to CN¥71.99 Down from CN¥93.60, the current price target is an average from 4 analysts. New target price is 125% above last closing price of CN¥32.02. Stock is down 52% over the past year. The company is forecast to post earnings per share of CN¥1.88 for next year compared to CN¥1.96 last year. Reported Earnings • Aug 28
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: CN¥0.73. Revenue: CN¥515.4m (up 15% from 2Q 2023). Net income: CN¥63.1m (down 43% from 2Q 2023). Profit margin: 12% (down from 25% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 37%. Earnings per share (EPS) also missed analyst estimates by 34%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Price Target Changed • Aug 16
Price target increased by 12% to CN¥104 Up from CN¥93.60, the current price target is an average from 4 analysts. New target price is 188% above last closing price of CN¥36.31. Stock is down 41% over the past year. The company is forecast to post earnings per share of CN¥2.77 for next year compared to CN¥1.96 last year. Buy Or Sell Opportunity • Jul 02
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 33% to CN¥73.70. The fair value is estimated to be CN¥95.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 39% over the last 3 years. Earnings per share has grown by 40%. Revenue is forecast to grow by 111% in 2 years. Earnings are forecast to grow by 93% in the next 2 years. Announcement • Jun 28
Anhui Huaheng Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Anhui Huaheng Biotechnology Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 Announcement • Jun 05
Anhui Huaheng Biotechnology Co., Ltd., Annual General Meeting, Jun 25, 2024 Anhui Huaheng Biotechnology Co., Ltd., Annual General Meeting, Jun 25, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Hefei, Anhui China Reported Earnings • Apr 22
First quarter 2024 earnings: EPS and revenues miss analyst expectations First quarter 2024 results: EPS: CN¥0.55 (up from CN¥0.52 in 1Q 2023). Revenue: CN¥500.8m (up 25% from 1Q 2023). Net income: CN¥86.6m (up 6.6% from 1Q 2023). Profit margin: 17% (down from 20% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 37%. Earnings per share (EPS) also missed analyst estimates by 30%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 29
Anhui Huaheng Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 22, 2024 Anhui Huaheng Biotechnology Co., Ltd. announced that they will report Q1, 2024 results on Apr 22, 2024 Buy Or Sell Opportunity • Mar 08
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 7.1% to CN¥121. The fair value is estimated to be CN¥98.58, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 40%. Revenue is forecast to grow by 117% in 2 years. Earnings are forecast to grow by 86% in the next 2 years. Reported Earnings • Feb 24
Full year 2023 earnings: EPS in line with expectations, revenues disappoint Full year 2023 results: EPS: CN¥2.86 (up from CN¥2.04 in FY 2022). Revenue: CN¥1.94b (up 37% from FY 2022). Net income: CN¥450.7m (up 41% from FY 2022). Profit margin: 23% (in line with FY 2022). Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 37% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥120, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 12x in the Chemicals industry in China. Negligible returns to shareholders over past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥91.34 per share. Buy Or Sell Opportunity • Feb 06
Now 31% overvalued after recent price rise Over the last 90 days, the stock has risen 11% to CN¥120. The fair value is estimated to be CN¥91.34, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 45% over the last 3 years. Earnings per share has grown by 41%. Revenue is forecast to grow by 120% in 2 years. Earnings are forecast to grow by 86% in the next 2 years. Reported Earnings • Oct 26
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2023 results: EPS: CN¥0.81 (up from CN¥0.56 in 3Q 2022). Revenue: CN¥514.3m (up 45% from 3Q 2022). Net income: CN¥128.7m (up 46% from 3Q 2022). Profit margin: 25% (in line with 3Q 2022). Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) exceeded analyst estimates by 13%. Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Reported Earnings • Aug 29
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: EPS: CN¥0.70 (up from CN¥0.47 in 2Q 2022). Revenue: CN¥449.6m (up 25% from 2Q 2022). Net income: CN¥110.0m (up 49% from 2Q 2022). Profit margin: 25% (up from 21% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 6.4%. Earnings per share (EPS) exceeded analyst estimates by 12%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Announcement • Jun 28
Anhui Huaheng Biotechnology Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023 Anhui Huaheng Biotechnology Co., Ltd. announced that they will report first half, 2023 results on Aug 29, 2023 Valuation Update With 7 Day Price Move • Jun 27
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CN¥84.17, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 3.8% over the past year. Price Target Changed • Jun 07
Price target increased by 13% to CN¥146 Up from CN¥130, the current price target is an average from 4 analysts. New target price is 30% above last closing price of CN¥112. Stock is up 54% over the past year. The company is forecast to post earnings per share of CN¥3.11 for next year compared to CN¥2.03 last year. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.75 (vs CN¥0.51 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.75 (up from CN¥0.51 in 1Q 2022). Revenue: CN¥400.3m (up 48% from 1Q 2022). Net income: CN¥81.2m (up 47% from 1Q 2022). Profit margin: 20% (in line with 1Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Chemicals industry in China. Reported Earnings • Mar 01
Full year 2022 earnings released: EPS: CN¥2.94 (vs CN¥1.70 in FY 2021) Full year 2022 results: EPS: CN¥2.94 (up from CN¥1.70 in FY 2021). Revenue: CN¥1.42b (up 49% from FY 2021). Net income: CN¥319.0m (up 90% from FY 2021). Profit margin: 23% (up from 18% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China. Price Target Changed • Jan 20
Price target increased to CN¥184 Up from CN¥165, the current price target is an average from 4 analysts. New target price is 12% above last closing price of CN¥165. Stock is up 62% over the past year. The company is forecast to post earnings per share of CN¥2.64 for next year compared to CN¥1.70 last year. Announcement • Nov 17
Anhui Huaheng Biotechnology Co., Ltd. announced a financing transaction Anhui Huaheng Biotechnology Co., Ltd. announced a private placement of A shares on November 15, 2022. The transaction has been been approved by the resolutions of the 2nd extraordinary shareholders meeting of 2022. Price Target Changed • Nov 16
Price target increased to CN¥165 Up from CN¥102, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of CN¥157. Stock is up 82% over the past year. The company is forecast to post earnings per share of CN¥2.44 for next year compared to CN¥1.70 last year. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. 1 independent director (6 non-independent directors). Independent Director Qifeng Zhang was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.81 (vs CN¥0.37 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.81 (up from CN¥0.37 in 3Q 2021). Revenue: CN¥354.9m (up 47% from 3Q 2021). Net income: CN¥88.0m (up 120% from 3Q 2021). Profit margin: 25% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Valuation Update With 7 Day Price Move • Oct 25
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥153, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 15x in the Chemicals industry in China. Total returns to shareholders of 161% over the past year. Reported Earnings • Aug 18
Second quarter 2022 earnings released: EPS: CN¥0.68 (vs CN¥0.32 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.68 (up from CN¥0.32 in 2Q 2021). Revenue: CN¥358.5m (up 67% from 2Q 2021). Net income: CN¥73.8m (up 138% from 2Q 2021). Profit margin: 21% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 38%, compared to a 41% growth forecast for the Chemicals industry in China. Price Target Changed • Jun 18
Price target increased to CN¥110 Up from CN¥102, the current price target is an average from 3 analysts. New target price is 15% below last closing price of CN¥129. Stock is up 169% over the past year. The company is forecast to post earnings per share of CN¥2.24 for next year compared to CN¥1.70 last year. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥111, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 109% over the past year. Reported Earnings • May 02
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: CN¥0.51 (up from CN¥0.34 in 1Q 2021). Revenue: CN¥270.4m (up 43% from 1Q 2021). Net income: CN¥55.2m (up 78% from 1Q 2021). Profit margin: 20% (up from 16% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 47%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Over the next year, revenue is forecast to grow 38%, compared to a 42% growth forecast for the industry in China. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Apr 20
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥1.70 (up from CN¥1.50 in FY 2020). Revenue: CN¥954.1m (up 96% from FY 2020). Net income: CN¥168.2m (up 39% from FY 2020). Profit margin: 18% (down from 25% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 47%. Earnings per share (EPS) also surpassed analyst estimates by 12%. Over the next year, revenue is forecast to grow 35%, compared to a 48% growth forecast for the industry in China. Reported Earnings • Feb 24
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥1.69 (up from CN¥1.50 in FY 2020). Revenue: CN¥954.3m (up 96% from FY 2020). Net income: CN¥167.5m (up 38% from FY 2020). Profit margin: 18% (down from 25% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 47%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Over the next year, revenue is expected to shrink by 14% compared to a 47% growth forecast for the industry in China. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.37 (vs CN¥0.35 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥241.5m (up 111% from 3Q 2020). Net income: CN¥39.9m (up 42% from 3Q 2020). Profit margin: 17% (down from 25% in 3Q 2020). Valuation Update With 7 Day Price Move • Sep 10
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥73.20, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 22x in the Chemicals industry in China. Valuation Update With 7 Day Price Move • Aug 24
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥65.93, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 20x in the Chemicals industry in China. Valuation Update With 7 Day Price Move • Jul 12
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥53.61, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 30x in the Chemicals industry in China. Valuation Update With 7 Day Price Move • May 18
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥50.68, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 28x in the Chemicals industry in China.